ZEISS has completed the acquisition of D.O.R.C. (Dutch Ophthalmic Research Center) that includes the EVA NEXUS platform, one of the...
Read moreA single-dose gene therapy for neovascular age-related macular degeneration (nAMD) is now in Phase 3 clinical trials and, if approved,...
Read moreRANZCO’s Referral Pathway for Age-Related Macular Degeneration (AMD) Management has been updated as Australia gears up for the first approved...
Read moreA UNSW-developed molecule that could be administered via an eye drop for neovascular age-related macular degeneration (nAMD) is being commercialised...
Read moreBayer’s high dose aflibercept 8 mg – now approved in the European Union and US – has been labelled...
Read moreAt the completion of this CPD activity, optometrists will understand the clinical utility of optical coherence tomography angiography (OCT-A),...
Read moreBayer’s higher dose aflibercept 8 mg with extended treatment intervals is set for approval in the European Union (EU) for...
Read moreWhether ophthalmologists are scanning a three-month-old or elderly patient, the ability of Optos ultra-widefield imaging devices to capture 200°...
Read moreApellis Pharmaceuticals has responded to “positive” 24-month data for its pioneering geographic atrophy (GA) therapy published in The Lancet, demonstrating...
Read moreAn investigation into rare events of retinal vasculitis linked to Apellis Pharmaceutical’s new therapy, SYFOVRE, for geographic atrophy (GA) has...
Read moreInsight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.
© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited
© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited